Intranasal Olopatadine-Mometasone in the Treatment of Seasonal Allergic Rhinitis

Abstract

Objective: To review the pharmacology, efficacy, and safety of intranasal olopatadine hydrochloride-mometasone furoate (OM) combination in the treatment of seasonal allergic rhinitis (SAR). Data sources: The PubMed database and ClinicalTrials.gov were searched using the following terms: mometasone + olopatadine, GSP301, mometasone furoate, and olopatadine hydrochloride. Study Selection and Data Extraction: Articles published in English between January 1987 and August 2022 related to pharmacology, safety, and clinical trials were assessed. Data Synthesis: In 2 phase II clinical trials, twice-daily (BID) and once-daily (QDay) intranasal OM demonstrated significant improvements in reflective total nasal symptom score (rTNSS) (BID P < 0.001 and QDay P < 0.001) and instantaneous total nasal symptom score (iTNSS) (BID P < 0.001 and P < 0.0001; QDay P < 0.001 and P < 0.0001). In 2 phase III clinical trials, BID OM showed significant improvements in rTNSS vs. placebo ( P < 0.001), olopatadine monotherapy ( P = 0.03 and P = 0.003), and mometasone monotherapy ( P = 0.02 and P = 0.059). Relevance to Patient Care and Clinical Practice: OM is indicated for treatment of SAR symptoms. Caution with use must be considered for certain high-risk patients, existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. Due to its quick and sustained onset of action, OM may be an ideal agent for initial treatment of moderate-severe SAR for patients 12 years and older. Conclusion: OM significantly improves SAR symptoms and is a viable treatment option in short-term SAR.